Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: The efficacy of tocilizumab in refractory chronic noninfectious uveitis has been previously reported, but no data comparing intravenous and subcutaneous tocilizumab in uveitis are available.
Results: We report a case series of patients with chronic noninfectious uveitis with incomplete efficacy of subcutaneous tocilizumab, improved after switching to intravenous routes. Improvement of visual acuity was observed with intravenous tocilizumab for all patients. Half of the patients could stop corticosteroids. Rapid efficacy of intravenous tocilizumab was observed, between 2 and 3 months.
Conclusion: In uveitis, tocilizumab administration could be optimized by a switching from a subcutaneous to an intravenous administration route.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354347 | PMC |
| http://dx.doi.org/10.1186/s12348-023-00336-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Laboratory approaches in desensitization for ABO-incompatible transplantation.
Clin Transplant Res
September 2025
Department of Laboratory Medicine, Pusan National University School of Medicine, Busan, Korea.
ABO-incompatible transplantation, once considered contraindicated due to the risk of hyperacute rejection, has become a viable option owing to advances in immunosuppression and desensitization methods. Accurate measurement and effective reduction of anti-ABO isoagglutinin titers are essential for the success of ABO-incompatible transplantation. This review summarizes the principles of hemagglutination and the measurement of isoagglutinin titers, highlighting variables that influence agglutination sensitivity.
View Article and Find Full Text PDFFour bispecific antibodies (BsAbs) are approved for the treatment of relapsed refractory multiple myeloma (RRMM), but their use is associated with infection risks, requiring mitigation strategies. This single-center retrospective study evaluated the incidence, etiology, and risk factors for infections in 158 RRMM patients treated with BsAbs. A total of 101 patients received BCMAxCD3 BsAbs (teclistamab and elranatamab), and 57 GPRC5DxCD3 BsAb (talquetamab).
View Article and Find Full Text PDFImmune Checkpoint Inhibitor-Induced Myositis Myocarditis and Myasthenia Gravis (MMM) Overlap Syndrome in a Rural District General Hospital: An Institutional Case Series Involving Four Patients.
Cureus
August 2025
Acute Oncology, Hywel Dda University Health Board, Haverfordwest, GBR.
Immune checkpoint inhibitors (ICIs) are commonly used for the treatment of some advanced cancers. Although effective, they can cause side effects. This case series describes four patients treated for ICI-induced myositis, myocarditis and myasthenia gravis (MMM) overlap syndrome at a rural general hospital in the United Kingdom between 2023 and 2025.
View Article and Find Full Text PDFAdvances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury.
Clin Exp Med
August 2025
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310029, Zhejiang, China.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, significantly improving patient survival. However, their use is frequently associated with immune-related adverse events, including immune checkpoint inhibitor-induced liver injury (ICI-DILI), which poses substantial clinical challenges. While corticosteroid therapy remains the primary treatment for ICI-DILI, many patients with steroid-refractory cases, especially those involving non-hepatocellular injury, exhibit resistance to standard therapies.
View Article and Find Full Text PDF